Therapy of malignant ascites in vivo by 211At-labelled microspheres;Therapie maligner asziteszellen in vivo mit 211At-markierten mikrosphären

NuklearMedizin

Volumn 43, Issue 2, 2004, Pages 63-68

  Bredow, J ^a   Kretzschmar, M ^b   Wunderlich, G ^a   Dorr W ^c   Pohl, T ^a   Franke, W G ^a   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Ehrlich mouse ascites carcionoma; Microspheres; Radionuclide therapy

Indexed keywords

ASTATINE 211; MICROSPHERE; SERUM ALBUMIN; SERUM ALBUMIN MICROSPHERE B 20; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BETA RADIATION; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; EHRLICH ASCITES TUMOR; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; RADIATION INJURY; RADIOACTIVITY; TUMOR MODEL;

EID: 1942438605     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1624060     Document Type: Article

References (25)

1. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts - a long-term study. Acta Oncol 2000; 39: 741-5.
2. Behr TM, Sgouros G, Stabin MG et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res 1999; 5: 3031s-43s.
3. Beyer GJ, Dreyer R, Odrich H et al. Production of astatine at the Rossendorf-cyclotrone U-120. Radiochem Radioanal Letters 1981; 47: 63-6.
4. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977; 265: 620-1.
5. Bloomer WD, McLaughlin WH, Neirinckx RD et al. Astatine-211 - tellurium radiocolloid cures experimental malignant ascites. Science 1981; 212: 340-1.
6. Brown I. Astatine-211: its possible applications in cancer therapy. Int J Rad Appl Instrum (A) 1986; 37: 789-98.
7. 211At-markierten Humanserumalbumin-Mikrosphären - erste klinische Erfahrungen. NucCompact 1990; 21: 124-7.
8. Fekete E, Farringno MA. Studies on a transplantable teratoma of the mouse. Cancer Res 1952; 12: 438-43.
9. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1987; 13: 1767-73.
10. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. Int J Radiat Oncol Biol Phys 2001; 51: 271-8.
11. Langer EM, Rottgers HR, Schliermann MG et al. Cycling S-phase cells in animal and spontaneous tumours. I. Comparison of the BrdUrd and 3H-thymidine techniques and flow cytometry for the estimation of S-phase frequency. Acta Radiol Oncol 1985; 24: 545-8.
12. 211At in a murine intraperitoneal tumor model. Gynecol Oncol 1995; 57: 9-15.
13. Macklis RM, Kaplan WD, Ferrara JL et al. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys 1989; 16: 1377-87.
14. McDevitt MR, Sgouros G, Finn RD et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25: 1341-51.
15. Petrich T, Knapp WH, Potter E. Functional activity of human sodium/ iodide symporter in tumor cell lines. Nuklearmedizin 2003; 42: 15-8.
16. Rath FW, Bonk U, Coutelle C et al. Invasive tumor growth. Results of comparative histologic and electron microscopic as well as histo- and biochemical studies on the Ehrlich ascites carcinoma (EAC) implantation tumors in the mice. Dtsch Gesundheitsw 1971; 26: 905-10.
17. Roeske JC, Chen GT, Atcher RW et al. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys 1990; 19: 1539-48.
18. 211At produced in disposable internal and external bismuth targets. Nucl Med Biol 1998; 25: 89-93.
19. Taubert G, Krug H. Cell cycle peculiarities of the Ehrlich ascites tumour as revealed by cell counting and flow cytometry. Arch Geschwulstforsch 1986; 56: 1-8.
20. 32P colloids in a murine intraperitoneal tumor model. Gynecol Oncol 1992; 47: 366-72.
21. von Ardenne M, Reitnauer PG. On the effect of hyperthermia on Ehrlich mouse ascites cancer cells. Arch Geschwulstforsch 1965; 26: 184-5.
22. Weber DA, Eckerman KF, Dillman LT et al. MIRD - radionuclide data and decay schemes. New York: The Society of Nuclear Medicine Inc. 1989.
23. 211At-labeled particles. Radiobiol Radiother (Berl) 1988; 29: 212-4.
24. 211At-labelled albumin particles. Nucl Med Commun 1986; 7: 211-4.
25. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433-55.